GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Herantis Pharma Oyj HRTIS.HE · EUR

Health Care · Nasdaq Helsinki · 🇫🇮 Finland

Compare

1.19

+6.25%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Herantis Pharma Oyj — daily HRTIS

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Herantis Pharma Oyj on TradingView ↗
Market value
€28.7m
Last close × shares
Volume
43.9k
Shares, 9 Nov 2026

About Herantis Pharma Oyj

Its shares trade on Nasdaq Helsinki under the ticker HRTIS.HE. It has been listed since 11 June 2014. In the fiscal year to 31 December 2016, it reported revenue of €25,291 and a net loss of €4.4m. At that date it held total assets of €10.2m and shareholders' equity of €1.6m.

Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.

Figures and description from our data supplier, not checked against the company's own report.

More about Herantis Pharma Oyj →

Latest on Herantis Pharma Oyj

Our reporting

We have not reported on Herantis Pharma Oyj yet.

Next results

4 Mar 2027

Due on 4 Mar 2027. Analysts expect earnings of -0.07 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Herantis Pharma Oyj's ticker?

Herantis Pharma Oyj trades as HRTIS.HE on Nasdaq Helsinki, under ISIN FI4000087861.

What was Herantis Pharma Oyj's last closing price?

1.19 on 9 Nov 2026. The figure is in EUR and is never converted.

When does Herantis Pharma Oyj next report results?

Results are expected on 4 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.